

Company name Discure technologies *

Website www.discuremd.com *

CEO name Yuval Mandelbaum *

*

“Beyond Bones and Screws: Rethinking Orthopedic Repair“
Executive Summary / Investment Rational:

Discure Technologies is a clinical-stage medtech company developing a minimally invasive, implantable bioelectronic device to reverse degenerative disc disease (DDD). Backed by leading VCs and strategic investors, the company has raised a Series A round to support clinical trials in Europe and North America. Discure has received FDA Breakthrough Device designation and is part of the FDA TAP program, highlighting its potential to transform spine care.

- **Core Technology:**
Discure’s system delivers targeted electrical stimulation to the intervertebral disc, restoring fluid dynamics and reactivating biological repair mechanisms. By promoting the inflow of oxygen, nutrients, and fluid, it enables disc regeneration and reduces pain, offering a disease-modifying alternative to current treatments that only manage symptoms.
- **Product Profile/Pipeline:**
The Discure System is currently in first-in-human clinical trials in Europe and Canada. As a platform technology, it has the potential to address multiple orthopedic indications beyond DDD, including disorders of the hip, shoulder, and knee. The company’s pipeline reflects both broad clinical utility and significant commercial potential.
- **Business Strategy:**
Discure’s strategy centers on introducing a minimally invasive, outpatient, disease-modifying solution in a field with limited effective treatments. Its value is further amplified by a positive reimbursement environment, with high procedural reimbursement levels supporting adoption and market penetration.
- **What’s Next?**
Discure is progressing clinical trials and preparing to initiate a pivotal study in 2027 to support De Novo approval. Additional funding will be pursued to support this effort and drive the technology toward marketing authorization.